Pharma Focus Asia

WuXi XDC and HKSTP Partner to Foster Growth in Hong Kong's Bioconjugate Drug Sector

Wednesday, October 18, 2023

WuXi XDC, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in the field of Antibody-Drug Conjugates (ADC) and the broader bioconjugate market, has recently entered into a collaborative agreement with the Hong Kong Science and Technology Parks Corporation (HKSTP). This partnership aims to jointly advance the establishment of a comprehensive CRDMO value chain in Hong Kong.

This collaboration is intended to drive the development of ADCs and other bioconjugates in Hong Kong, utilizing WuXi XDC's extensive range of services and capabilities. The primary objective is to strengthen the biotechnology ecosystem in Hong Kong by fostering closer collaboration among industry players, academic institutions, and research organizations.

Under this agreement, companies within the HKSTP Park ecosystem will gain access to WuXi XDC's integrated platform, providing a one-stop solution for bioconjugate-based drug discovery, development, and analytical services. Additionally, WuXi XDC will offer consultation and training to biotechnology companies and research institutions in Hong Kong to expedite the transformation of scientific research findings into market-ready products.

Furthermore, HKSTP and WuXi XDC will deepen their collaboration by pooling resources and organizing joint activities. Together, they will outline a strategic roadmap to accelerate the establishment of a CRDMO value chain in Hong Kong. This, in turn, will streamline the drug development process and reduce the time required to bring innovative pharmaceutical products to market.

"We are delighted to partner with HKSTP to offer our one-stop platform, extensive industry expertise, and high-quality services to support local biotech firms. Hong Kong Science Park boasts a strong foundation in biotechnology with a focus on innovation. We are eager to solidify our partnership with HKSTP to drive the growth of the bioconjugate industry, ultimately benefiting patients worldwide."

"As the largest hub for technology research and development (R&D) and incubation in Hong Kong, HKSTP provides comprehensive state-of-the-art infrastructure and support services to the Innovation and Technology (I&T) ecosystem. We are excited to collaborate with WuXi XDC in assisting companies with technology transfer and expanding their market reach. By harnessing the strengths of both parties, we are committed to further enhancing the biotechnology ecosystem, positioning Hong Kong as a global hub for innovation and technology."

 

Source:prnewswire.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024